Clindamycin for Clindamycin-Sensitive Staphylococcus aureus Infections in Adults
For clindamycin-sensitive Staphylococcus aureus infections in adults, clindamycin is an effective treatment option at 600 mg PO/IV three times daily, particularly valuable for penicillin-allergic patients, skin and soft tissue infections, and bone/joint infections, though it should not be first-line for bacteremia or endocarditis due to risk of resistance emergence and treatment failure. 1, 2
Dosing and Administration
Standard adult dosing:
- 600 mg PO or IV every 8 hours (three times daily) 1, 3
- Duration: 5-14 days depending on infection type and clinical response 1
Primary Indications for Clindamycin
Skin and Soft Tissue Infections (SSTI)
- Outpatient purulent cellulitis: Clindamycin is a first-line option (A-I evidence) 1
- Complicated SSTI requiring hospitalization: 600 mg IV/PO TID for 7-14 days (A-III evidence) 1
- Advantage: Provides dual coverage for both streptococci and S. aureus when used alone 1
- Particularly effective when incision and drainage is performed concurrently 4
Bone and Joint Infections
- Osteomyelitis: 600 mg PO/IV TID (B-III evidence for adults) 1
- Septic arthritis: 600 mg PO/IV TID (B-III evidence) 1
- Must be combined with surgical debridement and drainage 1
Pneumonia
- Community-acquired pneumonia with S. aureus: 600 mg PO/IV TID (B-III evidence) 1
Critical Limitations and Contraindications
NOT Recommended for Bacteremia or Endocarditis
Clindamycin should NOT be used as primary therapy for S. aureus bacteremia or endocarditis due to:
- High risk of resistance emergence during therapy 5
- Documented relapses in endocarditis cases 5
- Lack of bactericidal activity compared to beta-lactams 5
Inducible Clindamycin Resistance - Critical Pitfall
Always perform D-zone testing (erythromycin-clindamycin disk approximation test) before using clindamycin 6, 7:
- If the isolate shows erythromycin resistance but clindamycin susceptibility, perform D-test
- Positive D-test indicates inducible resistance (erm genes present) - DO NOT use clindamycin 6
- Inducible resistance rates: 38.9% in MRSA, 15.4% in MSSA 7
- Failure to detect this leads to treatment failure 6, 7
Special Considerations
Penicillin Allergy
Clindamycin is the preferred alternative for penicillin-allergic patients with S. aureus infections 2, 5
Adjunctive Therapy Controversy
- Some guidelines suggest adjunctive clindamycin for toxin suppression in severe infections 8, 9
- Current evidence does NOT support routine adjunctive use: A 2022 pilot RCT showed no benefit in days free of SIRS, though mortality trended lower (0% vs 24%, small sample) 8
- Ongoing SNAP trial will provide definitive evidence 9
Clostridium difficile Risk
Major safety concern: Clindamycin carries significant risk of C. difficile-associated diarrhea 2:
- Use with extreme caution in elderly patients with severe illness 2
- Avoid in long-term ambulatory treatment (e.g., chronic osteomyelitis) unless patient can be closely monitored 5
- Contraindicated in patients with history of antibiotic-associated colitis 2
Comparative Effectiveness
For MSSA skin infections treated with incision and drainage: Clindamycin shows equivalent efficacy to TMP-SMX (25% vs 26% failure rates) 4
For MSSA bacteremia: Clindamycin showed similar microbiological cure rates (84%) compared to other anti-MSSA antibiotics, but this is NOT recommended practice given resistance concerns 10
Practical Algorithm
- Confirm susceptibility → Perform standard susceptibility testing PLUS D-zone test if erythromycin-resistant
- Identify infection type:
- SSTI/bone/joint/pneumonia → Clindamycin appropriate
- Bacteremia/endocarditis → Choose alternative (vancomycin, daptomycin, or beta-lactam)
- Assess patient factors:
- Penicillin allergy → Clindamycin preferred
- History of C. difficile or severe GI disease → Avoid
- Elderly with severe illness → Use with caution
- Dose: 600 mg PO/IV every 8 hours
- Monitor: Watch for diarrhea; if develops, discontinue immediately and evaluate for C. difficile 2